Neuberger Berman Group’s Aclaris Therapeutics ACRS Stock Holding History

Neuberger Berman Group’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102K	Sell	19,367 -2,695	-12%	-$12K	﹤0.01%	2245
2026 Q1	$82.7K	Buy	22,062 +3,107	+16%	+$10.5K	﹤0.01%	2091
2025 Q4	$57.1K	Buy	18,955 +6,251	+49%	+$15.8K	﹤0.01%	2047
2025 Q3	$24.1K	Buy	12,704 +48	+0.4%	+$84	﹤0.01%	2018
2025 Q2	$18K	Hold	12,656	–	–	﹤0.01%	2027
2025 Q1	$19.4K	Hold	12,656	–	–	﹤0.01%	1939
2024 Q4	$31.4K	Hold	12,656	–	–	﹤0.01%	1898
2024 Q3	$14.6K	Hold	12,656	–	–	﹤0.01%	1911
2024 Q2	$13.9K	Buy	12,656 +141	+1%	+$166	﹤0.01%	1885
2024 Q1	$15.5K	Sell	12,515 -23,923	-66%	-$28.5K	﹤0.01%	1817
2023 Q4	$38.3K	Buy	+36,438	New	+$111K	﹤0.01%	1835
2017 Q2	–	Sell	-40,000	Closed	-$1.19M	–	1587
2017 Q1	$1.19M	Buy	40,000 +27,000	+208%	+$778K	﹤0.01%	1112
2016 Q4	$353K	Hold	13,000	–	–	﹤0.01%	1375
2016 Q3	$333K	Buy	+13,000	New	+$276K	﹤0.01%	1374

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Neuberger Berman Group's ACRS Position: Q2 2026 in Review

Neuberger Berman Group reduced its Aclaris Therapeutics (ACRS) stake by 12% in Q2 2026, selling an estimated $12K and leaving 19,367 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

Neuberger Berman Group first reported a position in ACRS in Q3 2016 and has held it in 14 quarters since. The position peaked at $1.19M in Q1 2017. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Neuberger Berman Group held 19,367 shares of Aclaris Therapeutics worth $102K as of Q2 2026.
Neuberger Berman Group sold 2,695 Aclaris Therapeutics shares in Q2 2026, an estimated $12K.
Aclaris Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2245 holding.
Neuberger Berman Group first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 14 quarters since.
Neuberger Berman Group's Aclaris Therapeutics position peaked at $1.19M in Q1 2017.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.